Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9239485 | 0.88 | SIRT2 (0.44) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL877785 | 0.85 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL9239498 | 0.84 | SIRT2 (0.43) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL1038850 | 0.84 | SIRT2 (0.52) | SIRT2NMBR | |
| Hydrochloric Acid SCHEMBL8892437 | 0.84 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL9263718 | 0.82 | SIRT2 (0.45) | SIRT2 | |
| SCHEMBL6777569 | 0.82 | SIRT2 (0.48) | SIRT2NMBR | |
| SCHEMBL1342 | 0.82 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL7988581 | 0.82 | SIRT2 (0.42) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| Acetic Acid SCHEMBL7659782 | 0.82 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2NMBRENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016109361-A2 | 3-FLUORO-BENZONITRILE INHIBITORS OF 11-BETA-HYDROXYLASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| WO-2000001701-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| WO-1999035163-A1 | PHENYLALANINE DERIVATIVES | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| CN-1093701-A | Antiretroviral hydrazine derivative | CIBA GEIGY AG (CH) | 1994-10-19 | — | — | CN | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-5140034-A | Hydroxytryptamine receptor antagonists; psychological and gastrointestinal disorders | MERCK SHARP & DOHME LTD. (GB) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | SIRT2 1594/4885CYP11B1 405/4885CYP11B2 612/4885 |
| US-20150216847-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | SIRT2 4383/4885CYP11B1 317/4885CYP11B2 328/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | SIRT2 2715/4885CYP11B1 5/4885CYP11B2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.